2024-03-29T10:56:11Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00032053
2022-12-15T04:07:41Z
453:455
471:561:562
網膜静脈分枝閉塞症の黄斑浮腫に対するラニビズマブ硝子体内注射療法とマイクロパルス閾値下凝固併用療法 : 6カ月成績
COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION : 6-MONTH RESULT
COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION : 6-MONTH RESULT
Terashima, Hiroko
175125
新潟大学
博士(医学)
Purpose: To determine the efficacy of the combination therapy of intravitreal ranibizumab (IVR) and 577-nm yellow laser subthreshold micropulse laser photocoagulation (SMLP) for macular edema secondary to branch retinal vein occlusion cystoid macular edema.
Methods: Retrospective, consecutive, case–control study. Forty-six eyes of 46 patients with treatment-naive branch retinal vein occlusion cystoid macular edema were enrolled. The IVR + SMLP group consisted of 22 patients who had undergone both SMLP and IVR. Intravitreal ranibizumab group consisted of 24 patients who had undergone IVR monotherapy. Intravitreal ranibizumab therapy was one initial injection and on a pro re nata in both groups, and SMLP was performed at 1 month after IVR in the IVR + SMLP group. Preoperatively and monthly, best-corrected visual acuity and central retinal thickness were evaluated using swept source optical coherence tomography.
Results: Best-corrected visual acuity and central retinal thickness significantly improved at 6 months in IVR + SMLP and IVR groups. Best-corrected visual acuity and central retinal thickness were not significantly different between the two groups at any time points. The number of IVR injections during initial 6 months in IVR group (2.3 ± 0.9) was significantly greater (P = 0.034) than that in IVR + SMLP group (1.9 ± 0.8).
Conclusion: The combination therapy of IVR and SMLP can treat branch retinal vein occlusion cystoid macular edema effectively, by decreasing the frequency of IVR injections while maintaining good visual acuity.
RETINA 0:1–8, 2018
学位の種類: 博士(医学). 報告番号: 乙第2237号. 学位記番号: 新大博(医)乙第1809号. 学位授与年月日: 平成31年3月15日
RETINA. 2019, 39(7), 1377–1384.
新大博(医)乙第1809号
thesis
新潟大学
2019-03-15
2019-03-15
application/pdf
application/pdf
1
8
13101乙第2237号
https://niigata-u.repo.nii.ac.jp/record/32053/files/h30nmo1809.pdf
https://niigata-u.repo.nii.ac.jp/record/32053/files/h30nmo1809_a.pdf
eng
info:doi/10.1097/IAE.0000000000002165